Hepatitis C Community
Worth reading
About This Community:

This forum is for questions about medical issues and research aspects of Hepatitis C such as, questions about being newly diagnosed, questions about current treatments, information and participation in discussions about research studies and clinical trials related to Hepatitis. If you would like to communicate with other people who have been touched by Hepatitis, please visit our new Hepatitis Social/Living with Hepatitis forum

Font Size:
Blank Blank

Worth reading

Interferon-based Therapy Reduces or Reverses Liver Fibrosis over the Long-term in Chronic Hepatitis C Patients
Last updated: 15 July 2009

By Liz Highleyman hivandhepatitis.com


Interferon-based therapy reduced liver fibrosis progression over 5 years in hepatitis C patients who achieved sustained virological response, and most of those with advanced liver damage prior to treatment experienced fibrosis regression, according to findings presented at the 2009 Digestive Disease Week meeting (DDW 2009) last month in Chicago.

Research on the long-term effects of interferon-based therapy for chronic hepatitis C virus (HCV) infection have produced conflicting results. Several studies have shown that fibrosis progression may be slowed, halted, or even reversed in individuals who achieve sustained virological response (SVR). Outcomes in non-responders are less clear.

Mitchell Shiffman and colleagues from Virginia Commonwealth University Medical Center reported follow-up findings from a prospective cohort study (initiated in 1998) looking at long-term histological outcomes in chronic hepatitis C patients treated with conventional or pegylated interferon, with or without ribavirin.

A total of 755 patients underwent a baseline liver biopsy and received a single course of interferon-based therapy or no treatment. Of this initial group, 230 were followed without additional treatment for 5 years before undergoing a repeat biopsy. This group included 41 patients who declined therapy and 189 who received treatment but did not achieve SVR (continued undetectable HCV viral load 24 weeks after completion of therapy). Participants with no evidence of fibrosis at baseline who achieved SVR did not receive a repeat biopsy.

At baseline, untreated patients, treated patients without SVR, and treated patients who achieved SVR were not significantly different with respect to age (average 46 years), sex (55% male), and baseline HCV RNA (5.7 IU/ml).

However, inflammation, fibrosis, and serum ALT were lower in the untreated group (i.e., these patients were least likely to be deemed to require therapy). The SVR group had fewer African-Americans and people with HCV genotype 1 (i.e., these individuals were less likely to achieve sustained response). The analysis did not include patients with other causes of liver disease besides HCV, HIV-HCV coinfection, chronic kidney failure, or prior organ transplants.


Patients who achieved SVR continued to have undetectable HCV RNA throughout the 5 year follow-up period.

After 5 years, inflammation and fibrosis scores increased significantly in the untreated group (by 2.1 and 1.1, respectively) and the treated group without SVR (by 1.6 and 0.5, respectively).

More patients with no fibrosis at baseline and no treatment experienced liver disease progression (28% vs 11%).

Liver histology improved significantly in treated patients who achieved SVR.

After 5 years, all treated SVR patients with portal fibrosis and 80% with bridging fibrosis at baseline had no fibrosis.

20% of sustained responders experienced resolution of cirrhosis.

"Interferon treatment reduces the rate of histologic progression over 5 years compared to [no treatment], even in HCV patients with [no fibrosis]," the investigators concluded.

"Patients with HCV who achieve SVR, including those with [cirrhosis], resolve fibrosis, and after 5 years liver histology returns to normal in most patients without pre-existing [cirrhosis]," they added.

Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA; Department of Pathology, Virginia Commonwealth University Medical Center, Richmond, VA.


ML Shiffman, SB Hubbard, A Long, and others. The Long Term Effects of Interferon Based (IFNTx) Therapy on Hepatic Histology in Patients with Chronic Hepatitis C Virus. Results of a Five Year Prospective Evaluation on Fibrosis Progression and Fibrosis Regression. Digestive Disease Week (DDW 2009). Chicago. May 30-June 4, 2009. Abstract 7.
Related Discussions
3 Comments Post a Comment
683664 tn?1330969924
Yup.  Good read.  Thanks for posting this.
476246 tn?1418874514
Great. The more I read about these studies, the more I feel that tx is worth it.
Avatar m tn
I guess this blows the occult virus therory out of the water.
Post a Comment
Recent Activity
406584 tn?1399591666
10356 commented on msdelight's status
7 hrs ago
3060903 tn?1398568723
Nighthawk61 commented on mishymoshymarcy's status
16 hrs ago
3060903 tn?1398568723
Nighthawk61 I DO NOT KNOW THE WORD FEAR... Comment
May 05
Weight Tracker
Track your weight over time
Start Tracking Now
Top Hepatitis Answerers
683231 tn?1438659664
Auburn, WA
317787 tn?1460223707
163305 tn?1333672171
Rural Mural, CA
446474 tn?1446351282
San Francisco, CA
Avatar universal
1815939 tn?1377995399
Hepatitis C Community Resources